Research and development costs decreased from 21.9 million to 17.3 million. Henrik. Let's now turn to the commercial side, where we continue to build strong momentum across Europe and make real progress towards our long-term goal of profitability. We have seen a strong growth trajectory in the last three quarters, and our European business continues to grow, supported by positive clinical experience and peer-to-peer recommendations. Looking back, the third quarter is always affected by the vacation period, which is why it is encouraging to see growth and increased demand now in Q3 2025.
It's a clear sign of more markets contributing to our revenue stream following the inclusion of the EU guidelines in July.
Pepaxti has gained further recognition from leading myeloma experts.
This type of validation has a tangible effect in the field.
It strengthens awareness, drives clarity on the positioning of Pepaxti, and generates confidence among HCPs, which leads to new prescribers through peer-to-peer recommendations. All these factors are critical to our launch success, which support us in making a real difference for more and more patients, which in turn, drives uptake to generate shareholder value. We continue to build Oncopeptides around the European opportunity for Pepaxti, which we estimate at roughly 1.5 billion SEK annually.
There are, however, patients in need of Pepaxti also in the rest of the world, and we are working with current partners and finding new partners to address that unmet need and add revenue streams. The long-term value will be generated from our pipeline, which we are advancing in the pre-clinical setting with several exciting assets getting closer to the clinic outside of Europe. Our focus remains on concluding a partnership for Japan. Discussions are advancing well but take a lot of time due to internal processes and governance, and we are still in the late stage of the due diligence phase. The structure of the potential agreement follows market practice, including upfront and milestone payments and double-digit royalties, with the partner assuming all costs related to regulatory and commercial activities in Japan.
Japan represents a market roughly the size of Germany, with a well-defined path to approval agreed with the Japanese regulatory authorities and key opinion leaders supporting the unmet need for Pepaxti.
We are focused on concluding a deal that is mutually beneficial for both us and our partner, which will naturally also benefit patients in Japan. Let's move to an update on our European key markets.
Regarding market access, we have seen some very positive progress for Irish patients lately.
We had an early access program open to ensure HCPs could gain experience, to assess if they would support the unmet need for Pepaxti in Ireland. This support is critical to enable us to enter into price negotiations.
Ireland is a small and centralized market, and in a fairly short time, we have seen 12 patients being included in the EAP program. The data that has been submitted to the payer authority is very encouraging and KOLs are supporting the need, which once more confirms that Pepaxti delivers at or even beyond expectations in real life. We are discussing with HCPs in Ireland to publish the very encouraging data that they have generated, which can also support launches in other markets. We are hopeful that the strong evidence leads to access, but having said that, it commonly takes time and is usually very difficult to gain in Ireland.
We expect to know more within the coming quarters. As already mentioned, we hit an all-time high demand in July, followed by another all-time high demand in September. The vacation period in Europe, particularly in August, is temporarily affecting net sales growth. I will get more into details per country in a short while.
Important to note is that by the end of Q3, more than 550 patients have been treated since launch, and we are now truly making a difference for many patients in Europe with rare disease launches.
It is not only the effort of the company, but all launches are dependent on peer-to-peer recommendations.
These can originate from our own experience, published real-world data, or guidelines as some of the most important sources for such recommendations. And as already mentioned in the last quarter, we saw great progress in these areas.
Yes, we have two real-world data sets published and presented at the International Myeloma Society.
We achieved the inclusion of Pepaxti in the updated EMA guidelines in July, securing a strong recommendation in our desired position, which is excellent as these guidelines are now being referenced across Europe. One more important aspect for the mid and long-term delivery of the launch is to close evidence gaps.
That appears due to how the treatment landscape evolves, and it can support differentiation and inform treatment decisions over time. As a small company, we don't see a return on investment in setting up our own studies to close these gaps, but we do invest in ideas that fit our strategy coming from external investigators. This type of study is very cost-effective for us and generates scientific engagement, which is also important for the launch. Here we see increased interest from KOLs to generate data on Pepaxti and the PDC platform, and we now have investigator-initiated trials contracted in all markets. Here is a heatmap illustrating the sales growth across Europe in Q3 compared to previous quarters, and I will now get into more details per market.
Germany remains our largest market.
It's the market most affected by the vacation period.
And when we look at our segment, we can conclude via sales data that the vacation period is affecting the overall multiple myeloma market.
We also observed a decline in demand in August. This is also the case for Pepaxti.
We anticipated this and are looking to catch up in Q4. Given the slowness in the market, it's important and encouraging to see how we are continuously broadening the prescriber base.
Increased experience in Germany has led to several RWD publications being generated currently. The effect on T cells is being explored further, illustrating how Pepaxti is differentiated from other alkylators by affecting not only the nuclear DNA but also the mitochondrial DNA. These are important scientific questions that will advance our scientific understanding and fuel our launch.
In addition, we have several proposals under review from German KOLs, which demonstrate the increased interest in Pepaxti and the PDC platform, interest that we actually lacked at launch. These are very encouraging signs.
As these studies have the potential to close important evidence gaps that can support our launch in the mid and long term and also support our pipeline development.
Finally, we do see good progress in awareness, which was confirmed and boosted by the annual German-speaking Hematology Congress taking place now in October. The majority of companies are focused on immunotherapy and early lines of treatment. And our symposium, which focused on real-life patients who are older and frailer than those in the clinical trials, attracted so many participants that we had to use the overflow room to accommodate everyone.
This is a sign that there is a great interest in and need to discuss the target patient profile of Pepaxti, highlighting the necessity to complement immunotherapy.
As mentioned, it's encouraging to see that quarter over quarter, our prescriber base is growing. What we can conclude is that there is still a lot of room to continue this trend, both through our own activities and peer-to-peer recommendations. The heat map for Germany is visualizing how we are broadening sales of Pepaxti.
Even though Germany is a scattered market and we have many customers, focusing on the highly populated areas is of utmost importance.
These areas are the most crowded, with many pharma companies working to build awareness, and at the same time, many physicians are starting to restrict access to pharma. The challenge for us is that we are a small company and the only company launching a PDC.
Well, there are many companies launching bispecifics. The opportunity, however, lies in the fact that we are unique. We have a unique product that truly delivers in real life, and where physicians gain experience, they appreciate Pepaxti and continue to use it. We have a resilient team.
We are continuing to capture potential step by step.
Italy is the second-largest market and was the strongest contributor to demand growth in the third quarter.
Italy is an excellent example of how better understanding and awareness of Pepaxti, due to positive clinical experience already ahead of launch and with a more centralized prescriber base, can directly translate into a change in prescribing behavior when physicians now get access to Pepaxti. In the third quarter, we reached 90% access at the hospital level, and we now only have one high-potential region left to fully unlock.
Looking at the uptake, the strong collaboration between our local field team and prescribers continues to drive performance, confirming that Pepaxti is making a meaningful difference for patients with encouraging real-world data from Italy, presented at the IMF Annual Meeting. This data highlights Pepaxti's effectiveness and tolerability in heavily pre-treated patients, further supporting uptake in peer-to-peer advocacy.
In Italy, we have several investigators from our clinical development program, and we already have one investigator-initiated trial ongoing to close an important evidence gap to conclude on Italy. We have a strong start to the launch and a very promising foundation to build on.
The heatmap visualizes the accumulated sales in variance sold per quarter and demonstrates the evolution of the Italian launch. We made our first sales in Q1, ahead of plan. We started to gain regional access in Q2, and we now have a fairly broad base of prescribers already in Q3.
Spain stands out as a model of scalability for our commercial approach.
We now have full regional access across the country. This means we have received orders from all the regions with multiple myeloma patients, marking another milestone achieved in Spain.
We see scientific progress and launch-supporting activities advancing in the real world. Data from Spanish investigators, presented at the IMS annual Meeting, is the first of its kind, as all patients were previously treated with a bispecific antibody. Given that this drug class was recently launched, we don't have data from our clinical program on how these patients respond to Pepaxti. This is why it's so important and very encouraging to see that also in this patient group, Pepaxti's effectiveness and safety are confirmed. Just like in Italy. We have an investigator-initiated trial running, and in Spain, the focus is not only on Pepaxti but also on generating evidence in the clinic for our PDC platform, which can support our partnership discussions for other PDCs. The Spanish heatmap is visualizing full coverage of the country, and now it's about increasing the number of prescribers and ensuring even more patients are getting Pepaxti already in the fourth line to continue to accelerate the sales uptake for Spain. Moving to partnerships.
In addition to the ongoing negotiations with Japanese partners, we continue to explore other deals.
In fact, earlier this week I attended BIO-Europe, where we had many interesting and promising first discussions with different types of partners for both Pepaxti and our pipeline.
There is an increased interest in exploring NK cell engagement. As a result of that, the T cell space is becoming crowded. In addition, indications with extremely high unmet needs like glioblastoma are of interest to many companies. In conclusion, it is not only us who find our pipeline strategically interesting, but many partners are also showing interest and want to understand the numerous opportunities we have at Oncopeptides.
Even better discussions will continue, and we will keep the market updated on our current partnerships in South Korea. Our partners, CBO, have launched an access program for Pepaxti, providing full financial support to patients with triple-class refractory multiple myeloma. The program marks Pepaxti's first formal introduction in Asia beyond the clinical development program, with the first patient being treated at Seoul Saint Mary's Hospital.
This initiative not only broadens Pepaxti's global footprint, but also underscores its recognition as a meaningful treatment option for patients with few remaining alternatives. The next step in South Korea is a regulatory submission, which our partner is working towards.
We continue to build our PDC platform with Pepaxti leading the way.
Serving as a proof of concept for the technology.
In parallel, we are advancing our SPiKEs platform, focusing on engagement for oncology, hematology, and autoimmune diseases.
Both programs illustrate our broader strategy to expand geographically, to form smart partnerships, and to innovate purposefully. I will not elaborate more on the pipeline right now, as I will get more into details in our upcoming capital markets update next week. And before I conclude, I would like to remind everyone about this event, which is on November the 13th from 9 to 12 Central European Time.
It will be an online event broadcast here from Stockholm featuring leading myeloma experts and key stakeholders. Oncopeptides and I will give an update on the future of Oncopeptides, focusing on opportunities beyond what is required today. If you haven't already, I encourage you to register via our website. It will be an insightful session on both our commercial progress and scientific roadmap. To summarize, we have growth momentum. We are now delivering the fourth consecutive quarter of double-digit growth, tracking towards profitability by the end of 2026. We have a strong European foundation.
Pepaxti is fully approved and reimbursed in key markets, representing about half of the total European opportunity, estimated at 1.5 billion SEK per year. We are expanding globally, with ongoing negotiations for Japan and established partnerships already in South Korea, Africa, and MENA.
We are demonstrating scientific progress with RWD publications, guideline inclusion, and investigator-initiated trials in all markets, which are strengthening the party's position. We have an innovative pipeline with next-generation PDCs and SPiKEs platform that offers long-term growth potential in oncology, hematology, and immunology, and with solid execution, disciplined cost management, and growing market endorsement.
Oncopeptides is well on track to deliver sustainable value creation.
That concludes the presentation, and I would like to open up for questions.